1980884-01-2
1980884-01-2
Chemical Structure
PI3Kδ/γ-IN-1
- CAS No.: 1980884-01-2
- Formula:C25H28N6O4S
- Molecular Weight:508.59
IUPAC Name: 2-((3-((4-hydroxypiperidin-1-yl)sulfonyl)phenyl)amino)-5,8,11-trimethyl-5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one
InChIKey: GHKMIOAEPALCFS-UHFFFAOYSA-N
SMILES: O=C1N(C)C2=CN=C(NC3=CC=CC(S(=O)(N4CCC(O)CC4)=O)=C3)N=C2N(C)C5=CC=C(C)C=C15
Biological Activity: PI3Kδ/γ-IN-1 is a potent, selective PI3K-δ/γ inhibitor for research of hematological malignancies.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PI3Kδ/γ-IN-1 | 99.39% | PI3Kδ/γ-IN-1 is a potent, selective PI3K-δ/γ inhibitor for research of hematological malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMU-MP-1 | 99.93% | XMU-MP-1 is a reversible and selective MST1/2 inhibitor with IC50s of 71.1 and 38.1 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMD16-5 | 98.20% | XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LRRK2-IN-1 | 99.04% | LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMD-17-51 | XMD-17-51 is a pyrimido-diazepinone compound that is able to modulate protein kinases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMD-17-51 TFA | 99.46% | XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ERK5-IN-1 | 99.55% | ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMD8-92 | 99.48% | XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with Kds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with Kds of 190, 600 and 890 nM, respectively. Anti-cancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aurora kinase inhibitor-8 | 98.01% | Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
XMD-12 | 99.32% | XMD-12 (compound 1) is an Aurora kinase (Aurora Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora A, B, and C kinases, with IC50 values of 5.6, 18.4, and 24.6 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ERK5 ligand-2 | ERK5 ligand-2 is an ERK5 ligand. ERK5 ligand-2 can serve as a ligand for the target protein in the synthesis of PROTAC ERK5 degraders, such as PPM-3 (HY-149616). ERK5 ligand-2 is suitable for use in cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
